 |
|
|
| |
A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders
|
| |
| |
Reported by Jules Levin
47th Annual Meeting of the European Association for the Study of the Liver · Barcelona, Spain · April 18-22, 2012
Fred Poordad1, Eric Lawitz2, Kris V. Kowdley3, Gregory T. Everson4, Bradley Freilich5, Daniel Cohen6, Sara Siggelkow6, Michele Heckaman6, Rajeev Menon6, Tami Pilot-Matias6, Thomas Podsadecki6, Barry Bernstein6
1: Cedars-Sinai Medical Center, Los Angeles, CA, 2: Alamo Medical Research, San Antonio, TX, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: University of Colorado Denver and University of Colorado Hospital, Aurora, CO, 5: Kansas City Gastroenterology & Hepatology, Kansas City, MO, 6: Abbott, Abbott Park, IL
|
| |
|
|
|
|
|
